Republished news from European biotech media <LABIOTECH.eu> Two targets, one solution: The rise of bispecific antibodies
A flourishing field: Bispecific antibodies market set to see rapid growth.
Her (Dr. Jeng Her, AP Biosciences CEO) believes that we are entering “the era of ‘Antibodies 2.0’, as these modalities become integrated components of multitudinous treatment paradigms and approaches, as monotherapies, antibody-drug conjugates (ADCs), and as combinations with other approaches.”
He said that part of the reason for this belief is because of the sudden increase in popularity of bispecific antibodies, driven by both advancements in antibody engineering and a deeper understanding of cancer biology. “Our ability to design and manufacture these sophisticated molecules has significantly improved, allowing us to target disease mechanisms more precisely and clear the threshold for entry into the clinic.”
In fact, even the FDA has said that, in the future, it anticipates there will be a spectrum of bispecific antibodies developed to prevent, treat, or diagnose diseases, and the agency has been encouraging drug development in this area. In 2021, it finalized guidance on bispecific antibody development programs, which discusses aspects of chemistry, manufacturing, and controls (CMCs) as well as nonclinical and clinical development programs. It also describes the challenges, such as immunogenicity (or causing an immune response) related to the novel structures. In addition, the guidance recommends types of data to support BsAb approvals.
So, it comes as no surprise that the bispecific antibodies market is set to see rapid growth. According to Grand View Research, the global bispecific antibodies market size was valued at $5.73 billion in 2022, and is expected to grow at a compound annual growth rate (CAGR) of 44% from 2023 to 2030. Grand View Research cites rising incidences of chronic diseases such as cancer, autoimmune disorders, and infectious diseases, rising demand for targeted therapies, as well as advancements in antibody engineering technologies, as being some of the major driving factors for this expected growth.
“Bispecific antibodies are more than just a technological advancement; they represent a new, potentially transformative paradigm that extends far beyond oncology,” stressed Her, adding that these dual-action drugs are already being incorporated into multiple therapeutic approaches from ADCs to cell therapies, and this is a trend that is only going to continue.
